ABSTRACT: We analyze the relationship between the supply of new technologies and health care utilization and spending, focusing on diagnostic imaging, cardiac, cancer, and newborn care technologies. As anticipated by previous research, increases in the supply of technology tend to be related to higher utilization and spending on the service in question. In some cases, notably diagnostic imaging, increases in availability appear associated with incremental utilization rather than substitution for other services. Policy efforts to assess and manage the availability of new technologies could benefit society where the additional spending produced by new services is not associated with strong quality improvements.
perspective, reporting on a series of analyses that investigate the relationship between the availability of specific technologies and equipment, on the one hand, and health care use and spending, on the other. We consider a range of technologies, from outpatient diagnostic imaging to inpatient radiation oncology facilities, linking measures of technology supply to spending for both elderly and nonelderly populations and examining whether changes in availability are related to changes in use and spending.
We report on relationships between technology availability and spending at several levels, from spending on the particular technology in question to overall health care spending. Building on previous literature, our results highlight important relationships between the availability of individual technologies and spending. Even taken individually, the availability of some specific technologies is associated with sizable spending growth. Our results also highlight the fact that measured relationships can vary when spending at different levels is assessed. While our results suggest that individual technologies are closely related to specific types of spending, they are also consistent with the view that technological change more broadly has an even stronger relationship with overall spending.
It is important to stress that costly advances in medical technology need not be "bad" for society if they produce comparable or greater benefits. While some have questioned the extent to which high medical spending in the United States has produced benefits in a broad sense, other recent work has suggested that some technological advances have produced important net benefits for society even after their substantial costs are taken into account. 3 While recognizing the difficulty of cleanly identifying all of the causal relationships in this area, we hope that these analyses reinforce important relationships that are part of the U.S. health care system and should continue to be part of policy discussions.
Analyzing Health Care Technology And Spending
We conducted a series of analyses that related a range of measures of technology availability to associated spending measures. 4 While in principle health care technologies can encompass everything from new strategies for organizing data to scientific advances in genetics to hospital equipment, here we examine the effects of infrastructure-intensive capabilities involved in diagnostic imaging and in the treatment of cardiac patients, cancer patients, and newborns. Specifically, we looked at the effects of changing availability of magnetic resonance imaging (MRI) and computed tomography (CT) scanners, cardiac catheterization facilities, percutaneous transluminal coronary angioplasty (PTCA) facilities, coronary artery bypass graft (CABG) facilities, hospitals with implantable cardioverter defibrillator (ICD) capabilities, cardiac intensive care units (CICUs), neonatal intensive care units (NICUs), radiation oncology facilities, and positron emission tomography (PET) scanners. We compiled measures of the availability of these W 3 -5 3 8 5 N o v e m b e r 2 0 0 3 services by metropolitan statistical area (MSA) by year for the period 1998-2001 using American Hospital Association (AHA) surveys, Medicare claims, and data on diagnostic imaging from Verispan LLC. We aimed to select technologies that have the potential to be important cost drivers because they are themselves costly or are used in the treatment of patients with serious and expensive conditions. 5 We also are constrained to examine technologies for which appropriate data are available during the study time period.
Nationwide, the availability of most of these technologies has risen over time, particularly diagnostic imaging. Moreover, the extent of changes in technology availability varies across MSAs: Some areas expand and contract over time, and some expand or contract faster than others. Exhibits 1 and 2 illustrate these changes over time and across states, respectively.
We relate changes in the availability of the technologies to measures of spending on those technologies, related technologies, and health care in general. We examine spending patterns in the commercially insured population under age sixty-five using data from a large national group health plan that has approximately three million covered lives per year from all fifty states. Ninety-four percent of these people are in preferred provider organization (PPO)-like arrangements, with 6 percent in point-of-service (POS) plans. Benefit designs do not vary substantively across areas. We also examine spending in the Medicare population, using data on a 10 percent national random sample of senior fee-for-service (FFS) Medicare beneficiaries. For spending measures derived from both sources, we use total paid claim amounts plus any required patient copayments, deductibles, or coinsurance amounts for inpatient, outpatient, and physician claims. Because of data limitations, we do not include pharmaceuticals in any of our spending measures. Where applicable, our spending measures include both professional and facility spending.
There is growth in spending over time, and there is considerable variation in spending in different parts of the country. Exhibit 2 also illustrates the variation in the growth in outpatient spending for the entire commercially insured population we study, for patients with any diagnostic imaging claims and for patients with cardiac diagnoses, respectively. 6 We conducted a series of regression analyses that examined the relationship between the amount of spending for different services and the availability of technology. In essence, these regression models were designed to ask whether spending increased more quickly in areas that had faster growth in the technologies than in areas with less rapid growth. 7 The results provide statistical evidence about the direction, size, and strength of any relationship between technology and spending. To illustrate the results, we computed the predicted size of the spending change associated with an increase in the availability of a technology by one unit per million population. 8 It is tempting in analyses such as these to interpret the relationships between technology availability and spending as causal. It is, after all, plausible that the availability of more technology in an area causes more use of that technology in ways not unlike those by which the supply of other health care personnel is sometimes hypothesized to create its own demand. However, as in most studies of this type, we cannot rule out the possibility that unobserved confounders lead to observed relationships that are not causal. For example, if the populations of some areas have stronger preferences for using health care, then their general demand could drive both technology availability and spending. We attempt to control for important potential confounders, including state fixed effects, to mitigate this difficulty, but we cannot entirely eliminate it.
Three Relationships Between Technology Availability And Spending
n Technology-specific spending. We begin by asking whether more availability of a given technology is associated with higher use of and more spending on that technology. Exhibit 3 summarizes key findings-specifically, the estimated percentage change in use of or spending on the given technology that our results indicate is associated with an increase of one unit per one million population. To illustrate, Exhibit 3 indicates that an increase of one freestanding (that is, nonhospital) MRI unit per million population is associated with an increase of 0.93 percent in per beneficiary spending on outpatient MRI among this commercially insured population.
The general pattern in our results is that more availability is associated with higher use and more spending. For diagnostic imaging, for both the commercial and Medicare plans, more availability of freestanding MRI facilities is associated with a higher number of outpatient MRI procedures per population and higher spending on outpatient MRI. 9 Taking the effects on the commercial and Medicare populations together and extrapolating based on average MRI spending, the percentage changes in spending we observe would mean that a one unit increase in the number of freestanding MRI units per million people is associated with an increase of about $32,900 per million beneficiaries per month, or approximately $395,000 per year.
Exhibit 3 also reports results from parallel analyses focusing on freestanding CT availability. Increases in freestanding CT units are significantly associated with increases in use of and spending on outpatient CT for both commercial plan and Medicare beneficiaries.
We next studied five technologies and capabilities that have roles in caring for cardiac patients. When we examine effects on use, for each technology we count the number of outpatient procedures plus the number of hospitalizations in which a given procedure was performed, among patients with a cardiac diagnosis. When we study spending, we compute the amount of spending on these procedures and hospitalizations among the same population.
In the commercial plan data, increases in the availability of cardiac catheterization labs are associated with increases in cardiac catheterization use and spending. Adding one hospital with a cardiac catheterization lab per million population is associated with an increase of 2.2 percent per beneficiary in the number of cardiac care hospitalizations that involve a cardiac catheterization procedure, evaluated for the MSA with average availability of in-hospital cardiac catheterization. We observe relationships in the same direction for PTCA, CABG, ICD, and CICU measures, although the results are not statistically significant. Results are stronger in the Medicare population. Greater availability of these technologies is significantly associated with higher use in all of the cases, and greater availability of PTCA, ICD, and CICU is associated with higher spending. The magnitudes of the relationships are relatively large. Evaluated at mean spending levels, adding one PTCA hospital per million population is associated with an increase in spending of about $1.3 million per 100,000 cardiac beneficiaries per year. Adding one ICD hospital per million population is associated with increases Tech-specific use for diagnostic imaging is the total number of outpatient procedures for the given service. Tech-specific spending is outpatient spending for the given service. Tech-specific cardiac use measures the number of outpatient procedures plus the number of hospitalizations involving the service in question, among patients with a cardiac diagnosis. Tech-specific cardiac spending includes spending on outpatient services plus the total costs of hospitalizations that included these services, among patients with a cardiac diagnosis. Tech-specific cancer use is the number of outpatient services plus the number of hospitalizations involving the service among cancer patients. Tech-specific cancer spending includes spending on outpatient services plus the total costs of hospitalizations that included these services, among patients with a cancer diagnosis. Cancer patients are those with claims data evidence of having lung cancer, prostate cancer, colorectal cancer, breast cancer, ovarian cancer, or lymphoma/leukemia. Tech-specific use for newborns is the number of NICU days per newborn. Tech-specific spending is NICU spending among newborns. a Verispan (1998 Verispan ( -2001 in spending of about $1.1 million per 100,000 cardiac beneficiaries per year.
Results from analysis of the availability of NICUs and cancer care technologies produced less conclusive results, with limited statistical significance. These lessthan-compelling findings could be related in part to the fact that there is comparatively less variation in the availability of these technologies during the research time period than was the case for cardiac and diagnostic imaging.
n "Category" spending and the potential for substitution. An important component of the total effect of any technology on use and spending is the extent to which it substitutes for other technologies, reducing total utilization, or complements other technologies, tending to increase total utilization. We explored these relationships in several ways. First, we explored the relationship between expanding MRI availability and use of CT scanning. Although these are distinct technologies that can have distinct uses, one could expect MRI to act as a partial substitute for CT scanning. We estimated regressions similar to those above, examining the relationship between freestanding MRI and CT availability and outpatient CT use and spending. Our results show that increases in the availability of freestanding MRI, controlling for the availability of CT, are associated with increases in CT use. That is, this evidence does not suggest that MRI availability offsets CT use but rather seems to suggest the opposite.
Second, we investigated the potential for substitution between PTCA and CABG, two alternative treatments for patients with cardiac disease. In the commercially insured population, we did find evidence for substitution, in that higher availability of PTCA is associated with substantial reductions in use of and spending for CABG and vice versa. We also found higher CABG availability associated with lower PTCA use in the Medicare population. However, higher PTCA availability was associated with higher CABG use in this population.
Another way to study these effects is to consider the relationship between technology availability and spending in a broader category to which each specific technology pertains. For example, for freestanding MRI, we measure spending on diagnostic imaging procedures. For cardiac catheterization, we measure total spending on patients with cardiac conditions. These measures are designed to capture direct effects on spending as well as other indirect effects (for example, substitution). These analyses may be instructive, since they involve broader categories of spending than the technology-specific analyses discussed earlier, but the potential here for confounding is also greater. An additional issue is the relatively high correlation among many of our technology measures, so that the measured relationships might reflect not only the relationship between the availability of a specific technology and category spending, but also the relationships of other cor- 
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"We find the strongest association between higher availability and more spending for freestanding diagnostic imaging." related technologies. Exhibit 4 reports some results of these analyses. For diagnostic imaging category spending, we study total spending for outpatient MRI, CT, ultrasound, and x-ray procedures. In the commercial plan population, an increase of one unit per million in the availability of MRI equipment is associated with an increase of 0.33 percent in diagnostic imaging spending. This relationship is much larger than that observed for MRI spending alone, particularly noting that it is relative to the higher baseline spending level of diagnostic imaging spending rather than just MRI spending. Results for the Medicare population are consistent and somewhat larger. Results for CT availability are also similar.
For cardiac technologies, we examine category effects by studying total spending for patients with cardiac diagnoses. Here, increases in the availability of cardiac services are most often associated with reductions in total spending on patients with cardiac diagnoses. This pattern might suggest some substitution of the measured technologies for other services contemporaneously, or use of these services might tend to reduce use of other future services. For NICUs, we studied relationships between availability and total spending for newborns. The estimated relationship is negative but statistically insignificant. For cancer, we examined total spending for cancer patients. In the commercial plan population, neither of the technology-specific measures was significantly associated with category spending, although increases in PET availability are associated with higher category spending in the Medicare population.
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n Total health care spending. Finally, we examined total spending measures, which include all spending for all inpatient, outpatient facility, and physician services for all patients in an area. Although the high potential for confounding in an analysis of such high-level measures makes drawing causal conclusions difficult, this kind of analysis could be instructive to the extent that each of our individual technology measures can be construed as capturing at least partially the broader level of technology availability in an area. These results could then be instructive in light of previous work underscoring the importance of the overall association between technological advancement and spending (Exhibit 4). 10 In the commercial plan population, greater availability of technologies is associated with higher total spending in all but two cases. These effects tend to be quite large, and much bigger than the technology-specific relationships reported in Exhibit 3. This pattern is consistent with the view that in addition to reflecting the availability of a specific technology, these measures also reflect an overall higher level of technology availability that is associated with higher spending. In the Medicare population, results are more mixed, with increases in the availability of many technologies associated with increased spending, although, notably, not for cardiac technologies.
Discussion
n Technology availability is associated with higher spending. We find that increases in the supply of specific technologies are frequently associated with increases in use of and spending on those technologies. Although many studies have identified advances in technology broadly as a major driver of health spending, this study links the availability of specific technologies to higher use and spending.
There are, however, a number of important nuances that should be noted as one considers approaches to containing rising health care costs that might target new technologies. First, relationships are not the same across technologies. We find the strongest association between higher availability and more spending for freestanding diagnostic imaging. We find much less evidence of such a relationship for NICUs and cancer technologies. It need not be that the availability of every new technology will be associated with higher use and spending. Some technologies might be easily amenable to expansions in their use with higher availability, while for other technologies the opportunities for use might be relatively fixed, so more of the technology cannot drive use as easily.
Second, the effects of the diffusion of an individual technology on spending could be felt beyond use of and spending on that particular technology. New technologies that substitute for other services could themselves see increased spending but offset some of that with reductions in spending elsewhere. Or new technologies could complement other technologies and drive up use and spending in other areas as well. Although we did not attempt comprehensive analyses of these issues, our results suggest the potential for such a complementary effect for diagnostic imaging. Our analysis of cardiac services, however, suggests a potential substitution. One potential explanation concerns differences in the types of services and patients: It might be easier to increment diagnostic imaging procedures than cardiac procedures. Third, prices may matter. In the commercially insured population we studied, a one-unit increase in the number of freestanding MRI machines per million is associated with a 0.93 percent increase in use of outpatient MRI but only a 0.10 percent increase in spending for it. This implies that prices for MRI are lower by about 0.83 percent in high-availability areas relative to low-availability areas, so that the effect of lower prices reduces the size of the relationship between availability and spending. Such a pattern is frequently observed in this commercially insured population. For some technologies, more availability could be increasing the amount of competition, leading to lower prices, although the potential for such an effect to produce meaningful impacts on spending could clearly vary across technologies. This effect, though, is not observed as commonly in the Medicare population, where the opposite pattern often occurs; this suggests that Medicare prices might be higher in areas with greater technology availability.
Fourth, context matters. Although our results for the commercial and Medicare populations are frequently similar, there are differences in the implied price dynamics just noted, and in other areas as well. This point highlights the fact that relationships identified for one population might not always hold for others. Differences across settings could arise for a number of reasons. In this case, for example, Medicare uses a relatively fixed pricing structure, whereas commercially insured patients are subject to a more flexible pricing structure.
As a general principle, these results should be viewed in the context of a long history of evidence suggesting that broad technology change is a key, perhaps the key, driver of health spending over time. In fact, our analyses of the relationship between our technology measures and overall spending are quite consistent with this evidence. Although we have examined only one specific aspect of technology expansion-growth in the supply of some new technologies-we believe that our results reinforce and amplify previous assessments of the importance of technological change and the need for continued attention to growth in technologies.
n Would reducing technology availability reduce spending? Observing a relationship between greater technology availability and more spending, one is tempted to conclude that increases in technology availability cause increases in use and spending. It then requires but a small step to conclude that efforts to slow the rate at which new equipment is made available would slow spending growth. Such an interpretation is certainly plausible but warrants careful consideration, since other explanations are also possible, and the actual effect of policies will be nuanced.
Some previous research has associated increases in the availability of physicians and hospital beds in an area with increases in use of medical services, giving rise to the widely discussed, if not conclusively demonstrated, possibility that supply in some circumstances can create its own demand. 11 It seems possible that some of the technologies studied here could increase use through such a mechanism. If new equipment tends to be used once it is put in place, greater availability of technology could lead to use and spending that would otherwise not have occurred.
Reductions in the availability of new technologies would then tend to reduce use of and spending for those technologies. (An important consideration, discussed below, is the extent to which the additional services produce important value for patients.)
It is also possible that associations between technology availability and spending arise for reasons that would not lead to the conclusion that reducing the availability of technology would reduce spending. One possibility is that other factors drive both greater use of technology and more spending. For example, some areas might have populations with a strong interest in purchasing health care. This could manifest itself as a climate in which health care providers find it profitable to buy new technologies. Although this would lead to greater availability of technology and higher spending in these areas, simply shutting off the supply of new technologies to the area need not reduce health care spending.
Another possibility is that some of the spending on the new technologies provides a means of compensating upstream technology development efforts, and is not solely compensating the equipment costs and variable costs associated with performing the procedures. Reducing availability would not reduce the costs for basic research and development (R&D) but would only spread these fixed costs over fewer machines and procedures.
This study, with its inherent methodological limits, cannot conclusively demonstrate the amount of savings that would be achieved if technology availability were reduced. We have included a number of controls for area characteristics and state fixed effects to attempt to control for bias from confounding, and we hope that this limits the extent to which the relationship we observe simply reflects underlying differences in characteristics. However, we recognize that changes over time in technology availability could also be confounded and that the controls we add, although they should be helpful, are unable to rule out this possibility. We lack the data to determine how much of the spending we observe is related to sunk upstream costs. At the same time, we believe that the existence of relationships between technology availability and spending, and the reasonable possibility that at least some of this relationship arises when the adoption of new equipment spurs demand for incremental procedures, calls for continued attention. It would be difficult for any study to conclusively predict the effects of reducing technology availability; however, in the face of steeply rising health care costs, prudence dictates that careful consideration continue to be given to the role of technology adoption.
n Quality effects are an important consideration. It is important to recognize the potential for benefits when evaluating technology. Higher spending need not be purely negative for society if the spending yields sufficient benefits. It is possible, even likely, that a large amount of health care spending does not produce higher quality. It is, nonetheless, also likely that some new technologies do produce value for patients. For example, some research argues that the benefits for society of several recent advances are substantial, and seemingly large enough to justify their large costs when compared with common cost-benefit benchmarks. 12 Perhaps the key question in evaluating increased use associated with the diffusion of new technologies is how the benefits compare to the costs. Any attempts to address the issue of technology availability and rising costs could end up badly misguided if implications for quality were not considered.
Policy Responses
Although providing detailed policy guidance is beyond the scope of our results, they do suggest some insights. Policy efforts should allow for the possibility that effects vary among technologies and that price dynamics and other aspects of the population and context can matter. It seems unlikely that appropriate one-sizefits-all approaches exist to address technology adoption. The most effective policy regimes will include serious technology evaluation and related efforts so that activities that would promote the growth of some technologies and retard others can be most effectively targeted.
Also, policy efforts should incorporate both the benefits and costs of new technologies. One typical argument is that a desire for high-technology care, coupled with the relatively low prices for medical care faced by well-insured consumers, tends to lead to the consumption of services whose value is much lower than the cost to society. However, effective price competition in health care markets, in which those receiving the benefits of services also have an appreciation for their cost, has the potential to reduce excess, inefficient use. For example, health plan policies that help consumers better identify the costs associated with their consumption choices, particularly for nonacute treatment decisions, may be effective policies to consider. In turn, these could affect the incentives associated with the purchase of new equipment.
In other cases, overuse could stem from individual consumers' and physicians' inability to identify the benefits of a new technology, so that they make individual choices that do not produce a collective set of socially optimal choices. Here, more generalized efforts could be warranted to assess the value of new technologies, disseminate information, and perhaps takes steps to collectively control the diffusion of new infrastructure and services.
A lt h o u g h w e b e l i e v e t h at t h i s r e se a r c h emphasizes important points across a number of technologies and spending measures, these analyses do not encompass all technologies or angles of inquiry. Our measures do not include pharmaceutical spending. This study also focused on data from a relatively narrow time window and a specific portion of each technology's life cycle. Results from studies with longer or different time frames could vary. More broadly, technology advance includes research and other development efforts that could independently drive up spending, which we do not directly address.
